Full Press Release Details
Accessibility: Skip TopNav
Summit Corporation PLC : Notice of Interim Results
August 21, 2013 02:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
NOTICE OF INTERIM RESULTS
Oxford, UK, 21 August 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy ('DMD') and C. difficile infection, will announce its interim results for the six months ended 31 July 2013 on Thursday, 22 August 2013.
Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 939 |
| Nomura Code Securities (Nominated Adviser and Joint broker) Chris Collins / Jonathan Senior / Giles Balleny | Tel: +44 (0)20 7776 1200 |
| Hybridan LLP (Joint broker) Claire Louise Noyce / William Lynne | Tel: +44 (0)207 947 4350 / 4361 |
| Peckwater PR (Financial public relations, UK) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
| MacDougall Biomedical Communications (US media contact) Michelle Avery | Tel: +1 781-235-3060 |